

EQUIPPED for Age-Friendly Prescribing in the ED



E. Camille Vaughan, MD, MS

Atlanta Site Director, Birmingham/Atlanta GRECC, Atlanta VA Health Care System
Associate Professor of Medicine
Division Director, Geriatrics & Gerontology
Department of Medicine
Emory University
USDeN Webinar – July 18th, 2023



Disclosure

- Funding for this project from
 - VA Health Services Research & Development
 - AHRQ
 - BCBS Rhode Island
 - VA Office of Geriatrics & Extended Care, Office of Rural Health
 - John A. Hartford Foundation
- Previous consultant for Becton Dickinson & Co. Mar 2021 Mar 2022
 - Not relevant for today's presentation

Objectives

- Describe prescribing safety concerns for older adults in the emergency department (ED)
- Identify frameworks available to understand factors influencing implementation of quality improvement projects
- Identify effective strategies to promote prescribing behavior change in the ED
- Determine resources needed to implement an age-friendly prescribing safety program in the ED









BACKGROUND



30.9% of adults 75 years and older visited an ED in 2019

26% of 65+ adults



Hastings, Smith et al. J Am Geriatr Soc 2013; 61:1515-1521. Aminzadeh and Dalziel. Ann of Emerg Med, 2002;39:3,238-247



The majority of older adults evaluated in the ED are not admitted to the hospital



45-65% of older adults are prescribed at least one new medication at the time of ED discharge






BACKGROUND

Time until first adverse event

▲ No new drug

No suboptimal pharmacotherapy

Suboptimal pharmacotherapy



Hastings, J Am Geriatr Soc, 2008





AGE-FRIENDLY HEALTH SYSTEMS

interfere with What Matters to the older adult, **Mobility**, or **Mentation** What **Matters Mobility** Medication 4Ms Framework Mentation Health Systems An initiative of The John A. Hartford Foundation and the Institute for Healthcare Improvement (IHI) in partnership with the American Hospital Association (AHA) and the Catholic Health Association of the United States (CHA).






If medication is necessary, use Age-

Friendly medications that do not


across settings of care.

GERIATRIC EMERGENCY DEPARTMENTS





THE BEERS CRITERIA







THE BEERS CRITERIA

Most widely cited criteria to assess inappropriate prescribing

Initially proposed for long-term care

Now promoted for all sites of geriatric care

Evaluated as a proxy for quality of prescribing

Examples include most muscle relaxants, chronic NSAIDS, many anticholinergic medications

Lund et al, Ann Pharmacother, 2011





Aim Statement



To decrease the proportion of potentially inappropriate medications (PIMs)* prescribed to Veterans aged 65 years of age and older at the time of discharge from the ED to 5% or less

Stevens, J Am Geriatr Soc, 2015


*PIMs defined by the American Geriatrics Society Beers Criteria® and adapted for the ED





The EQUIPPED program

Collaborative between Geriatric Research, Education and Clinical Sites (GRECCs) at 3 VAMCs Now expanded to 20 VA sites (8 new sites in FY20) and 5 civilian hospital systems







Influencing Prescribing Behavior: 3 Core Components



EDUCATION

Didactic education and academic detailing focused on reducing potentially inappropriate medications



CLINICAL DECISION SUPPORT

Discharge medication order sets designed to promote safer prescribing and provide alternatives to potentially inappropriate medications



INDIVIDUAL PROVIDER FEEDBACK

Providers receive monthly prescribing feedback reports that include individual prescribing habits, peer benchmarking, and alternate prescribing recommendations

Providers meet with the site champion at least once for 1:1 academic detailing





Clinical Decision Support: Discharge Order Sets

Electronic Decision Support Tools

Discharge medication order sets

- Point of prescribing education
- Links to online geriatric content


Avoid drug alert messages that require acknowledgement

ANTIBIOTICS GI Antibiotics SINUSITIS **GU Antibiotics** STD CARDIOLOGY CHF DERMATOLOGY CONTACT DERMATITIS **ECZEMA** *Patient info for Eczema POISON IVY *Patient info for poison ivy SHINGLES *Dermatome map for shingles

*Patient info for shingles

*Patient info wound care dressings *Patient info skin care guidelines

TINEA URTICARIA WOUND CARE



*Patient info risk of falls VACCINE ORDERING MENU

*PATIENT INFO HANDOUTS AVAILABLE ON DESKTOP

PAIN/RHEIIMATOLOGY

ARTHRITIS/CHRONIC PAIN GOUT

PSYCHIATRY

DEPRESSION

GENERAL WARNINGS and CONSULTS

PULMONARY

ALLERGIC RHINITIS

UROLOGY

ERECTILE DYSFUNCTION INCONTINENCE URINE RETENTION

*Patient info urge suppression

*Patient info scheduled toileting


*Patient info bladder diary


*Patient info fluid management





Clinical Decision Support: Discharge Order Sets










Discharge Order Set – Cerner Site

i opical i	Medications	
	ildocaine topical (lidocaine 4% topical cream)	See Directions, Topical, TID, # 30 gm, Apply to affected area. Avoid application on sensitive areas, wash hands with soap and water after
	lidocaine topical (Lidoderm 5% topical film)	See Directions, Topical, qDay, PRN pain-mild, # 14 patch(es), Apply 1 patch to affected area up to 12 hours per day and remove, maxim
	Out of pocket cost >\$100, consider social work consult if necessary.	
	diclofenac topical (Diclofenac 1% topical gel)	See Directions, Topical, q6hr, PRN pain-mild, # 100 gm, Apply 2 grams to the skin over affected area. Not to exceed 8g in any single join
Oral Med		
	Acetaminophen	
	acetaminophen (acetaminophen 325 mg oral tablet)	= 2 tab(s), PO, q6hr, PRN pain-mild, # 28 tab(s), X 7 day(s) Do not combine with other acetaminophen products or exceed more than 3000 mg in 24 hours.
	♦ NSAIDS	
	ibuprofen (ibuprofen 200 mg oral tablet)	= 1 tab(s), PO, q6hr, PRN pain-mild, # 12 tab(s)
	Avoid use with GFR < 30 ml/min, h/o recent Ml, HTN, and HF.	
	✓ Muscle relaxant ✓ Muscl	
	Oo not use in ESRD on peritoneal dialysis.	
	Avoid in lieu of topical agents or superficial heat/ice.	
	baclofen (baclofen 5 mg oral tablet)	= 1 tab(s), PO, TID, PRN pain-mild, # 9 tab(s)
	For CrCl > 80 mL/min	
	a baclofen (baclofen 5 mg oral tablet)	= 1 tab(s), PO, BID, PRN pain-mild, # 6 tab(s)
	For CrCl 51-80 mL/min	
	baclofen (baclofen 5 mg oral tablet)	= 0.5 tab(s), PO, TID, PRN pain-mild, # 5 tab(s)
	For CrCl 30-50 mL/min	
	baclofen (baclofen 5 mg oral tablet)	= 0.5 tab(s), PO, BID, PRN pain-mild, # 3 tab(s)
	For CrCl < 30 mL/min	
	🥎 Opioid pain management	
	🚱 If prescribing opiate pain medication, consider prescribing prophylac	ctic medication to treat constipation. Do not combine with other acetaminophen products or exceed more than 3000 mg in 24 hours.
	acetaminophen-hydrocodone (Norco 5 mg-325 mg o	= 0.5 tab(s), PO, q6hr, PRN pain-severe, # 9 tab(s), May increase to 1 tab po q 6 hr for uncontrolled pain.
	oxyCODONE (oxyCODONE 5 mg oral tablet)	= 0.5 tab(s), PO, q8hr, PRN pain-severe, # 9 tab(s), May increase to 1 tab po q 8 hr for uncontrolled pain.
	G Constipation	
	Please use shortest effective dose and duration of treatment. Polyethy	ylene glycol can be combined with prune juice or sennosides.
	polyethylene glycol 3350 (MiraLax oral powder for rec	= 1 packet(s) 17 gm, PO, qDay, # 14 packet(s), Dissolve one packet in 4-8 oz of liquid.
	bisacodyl (Dulcolax Laxative 10 mg rectal suppository)	= 1 supp, PR, Once, # 2 supp, May repeat in 24 hours if no BM.
	senna (Senokot 8.6 mg oral tablet)	= 2 tab(s), PO, qHS, # 60 tab(s), X 30 day(s)






Adaptation of Clinical Decision Support

Top 5 Potentially Inappropriately Medications (PIMs) prescribed for Veterans > 65yo discharged from our Emergency Department are: **NSAIDS** MUSCLE RELAXANTS BENADRYL HYDROXYZINE **PHENERGAN** Do your part in helping us reach a rate of ZERO! Check out the **ED Geriatric Order Set for** alternatives



EQUIPPED Provider Feedback



Stevens, J Am Geriatr Soc, 2015 Burningham Z Clin Ther, 2020



EQUIPPED Provider Feedback



Potentially Inappropriate Medication (PIM)



Informed by an Evidence-Based List of Medications to Avoid in Older Adults Link to Publication

rovider Name:									
Drug Name	VA Drug Class	Rx Number	Issue Date	Fill Date	Days Supply	QTY Per Day	Recommendation	Quality of Evidence	Alternative Therapies
CYCLOBENZAPRINE HCL 10MG TAB	SKELETAL MUSCLE RELAXANTS				5	3.00	Avoid	Moderate: Risk of adverse events identified, but study consistency needs improvement	For acute mild or moderate pain—acetaminophen, nonacetylated salicylate (e.g., salsalate), propionic acid derivatives if no heart failure or eGFR > 30 mL/min and given with PPI for gastroprotection if used for > 7 days
MECLIZINE HCL 12.5MG TAB	ANTIVERTIGO AGENTS				4	8.00	Avoid	Moderate: Risk of adverse events identified, but study consistency needs improvement	Intranasal normal saline; Second-generation antihistamine (e.g., cetirizine, loratadine); Intranasal steroid (e.g., fluticasone, over the counter)



Problems? Feedback is Welcome! Click here to contact us.

If the provider has prescribed any PIMs that month, the feedback form will include the list of specific drugs prescribed





EQUIPPED VA Outcomes

Site	Pre-EQUIPPED	Post-EQUIPPED	p value*
Atlanta	11.8 (SD 1.8)	5.3 (SD 1.5)	<0.0001
Birmingham	8.9 (SD 1.9)	6.3 (SD 1.4)	0.0025
Bronx	7.4 (SD 1.7)	5.6 (SD 1.0)	0.04
Durham	8.3 (SD 0.8)	4.5 (SD 1.0)	<0.0001

^{*}p-value: Poisson regression including offset term for site's total number of prescriptions



Change in average monthly proportion of PIMs pre and post EQUIPPED in Atlanta 2.6%

Change in average monthly proportion of PIMs pre and post EQUIPPED in Birmingham 1.8%


Change in average monthly proportion of PIMs pre and post EQUIPPED in Bronx 3.8%

Change in average monthly proportion of PIMs pre and post EQUIPPED in Durham



Stevens, J Am Geriatr Soc, 2017





—Atlanta —Birmingham —Bronx —Durham

EQUIPPED VA Outcomes

Site	Pre-EQUiPPED	Post-EQUiPPED	p value*
Atlanta 92 months post	8.6 (SD 0.7)	5.5 (SD 1.1)	<0.0001
Birmingham 76 months post	9.7 (SD 2.5)	4.7 (SD 2.1)	<0.0001
Bronx 72 months post	7.6 (SD 1.1)	5.2 (SD 1.5)	<0.001
Durham 81 months post	9.1 (SD 1.1)	4.5 (SD 1.1)	<0.0001
Asheville 69 months post	7.9 (SD 1.3)	5.9 (SD 1.3)	<0.0001
CAVHS 65 months post	11.0 (SD 1.5)	8.7 (SD 1.8)	0.01
TVHS-Nashville 64 months post	6.6 (SD 1.0)	5.8 (SD 1.4)	0.02
TVHS-Murfreesboro 64 months post	11.1 (SD 0.8)	8.8 (SD 1.6)	<0.0001
Orlando 38 months post	8.1 (SD 1.4)	9.1 (SD 1.8)	0.008 (worse)
San Antonio 40 months post	7.7 (SD 1.3)	8.4 (SD 1.6)	0.06 (worse)
Cleveland 22 months post	8.7 (SD 1.0)	5.6 (SD 1.3)	<0.0001
New Orleans 19 months post	9.5 (SD 1.6)	4.4 (SD 1.4)	<0.0001

^{*}Poisson regression with total prescriptions as offset term



SPREAD

VA EQUIPPED Implementation

VA HSR&D Implementation study funded FY19 FY20 expansion to 8 additional VA sites

Non-VA EQUIPPED Implementation

- AHRQ R18 funding 2016-2019 Expansion to Epic sites, affiliates of VA GRECCs
 - Grady, Mount Sinai Hospital, Duke
- AHRQ R18: 2019-2021 (PI:Vandenberg)
 - Scaling EQUIPPED: Expansion to EUH and at 3 Mount Sinai sites

BCBS Rhode Island 2019 expansion (PI: E. Goldberg)





Evaluation Framework

- Implementation Scientist Michelle Kegler, PhD (Emory)
- RE-AIM
 - Reach
 - Effectiveness
 - Adoption
 - Implementation
 - Maintenance




Klein K, Sorra J, Acad Manag Rev. 1996

- Consolidated Framework for Implementation Research
 - Understand implementation facilitators
 and barriers
 Glasgow RE et al. Am J Public Health 1999

 Implementation Scientist George Jackson, PhD (Duke/Durham)

- Organizational Theory of Implementation Effectiveness
 - Organizational Readiness for Change as a key factor


Components of the Organizational Theory of Implementation Effectiveness (OTIE)






Methods for Implementation Evaluation

- Focus group with implementation team
- Provider surveys
- Evaluation of prescribing data
- Evaluation of meeting notes
- Combined measure to determine provider education
 - Gathered through attendance records and survey responses





Toolkit to Assess Readiness for EQUIPPED



Vandenberg AE et al. Int J Qual Health Care 2020

EQUIPPED Export Results


Enhancing the quality of prescribing practices for older adults discharged from the emergency department in Rhode Island

Elizabeth M. Goldberg MD, ScM¹ ♀ ☐ | Timmy R. Lin MPH¹ | Cheston B. Cunha MD² | Nadia Mujahid MD, AGSF³ | Natalie M. Davoodi MPH¹ ♠ | Camille P. Vaughan MD, MS⁴ ♠

TABLE 1 Characteristics of clinicians (n = 247)

(%)
(70)
9 (48.2%)
7 (27.1%)
1 (24.7%)
4 (90.7%)
3 (9.3%)
8 (92.3%)
9 (7.7%)

Change of potentially inappropriate medications (PIMs) rates by drug class between pre-implementation and post-implementation periods



Early prescribing outcomes after exporting the EQUIPPED medication safety improvement programme

Camille P Vaughan, ^{1,2} Ula Hwang, ^{3,4} Ann E Vandenberg, ¹ Traci Leong, ⁵ Daniel Wu, ¹ Melissa B Stevens, ^{1,2} Carolyn Clevenger, ⁶ Stephanie Eucker, ⁷ Nick Genes, ⁸ Wennie Huang, ⁷ Edidiong Ikpe-Ekpo, ⁹ Denise Nassisi, ⁸ Laura Previl, ⁷ Sandra Rodriguez, ¹⁰ Martine Sanon, ⁸ David Schlientz, ⁷ Debbie Vigliotti, ¹¹ S Nicole Hastings^{7,12}

Table 1	Aggregate pre-EQUIPPED and post-EQUIPPED PIM prescribing and specific PIM drug classes at each
impleme	entation site

	Pre-EQUIPPED (%) (95% CI for All PIMs)*	Post-EQUIPPED (%) (95% CI for All PIMs)*	P value†
Site 1			
All PIMs	5.6 (5.0 to 6.3)	5.1 (4.7 to 5.5)	0.02
Benzodiazepine	16.6	9.5	0.04
Skeletal muscle relaxant	34.4	36.9	0.44
Antihistamine	15.8	13.4	0.15
Site 2			
All PIMs	5.8 (5.0 to 6.6)	5.4 (4.8 to 6.0)	0.62
Benzodiazepine	16.9	10.0	0.09
Skeletal muscle relaxant	21.9	21.3	0.84
Antihistamine	49.3	49.2	0.57
Site 3			
All PIMs	7.3 (6.4 to 9.2)	7.5 (6.6 to 8.4)	0.64
Benzodiazepine	17.3	12.0	0.05
Skeletal muscle relaxant	24.5	14.5	0.04
Antihistamine	38.2	43.2	0.52





Prescribing Outcomes from EQUIPPED2 (AHRQ: Vandenberg (PI)

- Traditional in New EHR (Cerner)
- Hub and Spoke model at Established Site

	% of all PIMs at baseline	Pre-EQUIPPED (%) (95% CI for all medications)*	Post-EQUIPPED (%) (95% CI for all medications)*	Pre- to Post change p-value**
Traditional: Site 1				
All PIMs	100	8.86 (8.12-9.60)	3.59 (3.59-9.60)	< 0.0001
Skeletal Muscle Relaxant	37.8 (33.6-42.2)	3.34 (2.89-3.84)	.85 (.59-1.18)	<.0001
Anticholinergic Antihistamine	20.8 (17.3-24.6)	1.8 (1.5-2.2)	1.4 (1.1-1.8)	.1272
Benzodiazepine	15 (12.03-18.34)	1.3 (1.05-1.65)	.33 (.1856)	<.0001
Anticholinergic Antispasmodic	10.2 (7.72-13.13)	.9 (.67-1.18)	.74 (.5-1.06)	.473
GI Motility	8 (5.82-10.73)	.7 (.5196)	.4 (.2263)	.0562
Spread: Site 1				
All PIMs	100	12.20 (11.20-13.19)	7.13 (6.14-8.14)	< .0001
Anticholinergic Antihistamine	32.3 (28.3-36.5)	3.9 (3.4-4.5)	3.4 (2.7-4.1)	.2578
Non-Steroidal Anti-	29.1 (25.2-33.2)	3.5 (3.0-4.1)	2.0 (1.5-2.6)	.0004
Inflammatory Drugs				
Skeletal Muscle Relaxant	27.1 (23.3-31.2)	3.3 (2.8-3.9)	1.1 (.8-1.6)	<.0001
Benzodiazepine	8.7 (6.46 -11.51)	1.1 (0.77-1.4)	.3 (0.17-0.66)	.0021
GI Motility	1.2 (0.52-0.02)	.1 (0.06-0.31)	.1 (0.01-0.27)	.7186
Spread: Site 2				
All PIMs	100	11.30 (10.14-12.56)	7.48 (6.35-8.78)	.04466
Anticholinergic Antihistamine	32.2 (26.99-37.72)	3.6 (2.96-4.42)	3.9 (3.08-4.90)	.7068
Non-Steroidal Anti-	30.9 (25.77-36.37)	3.5 (2.83-4.25)	2.0 (1.46-2.78)	.0059
Inflammatory Drugs	22 5 /40 02 27 (4)	2 5 /4 00 2 24)	0.77 (0.45.4.27)	. 0004
Skeletal Muscle Relaxant	22.5 (18.03-27.61)	2.5 (1.98-3.21)	0.77 (0.45-1.27)	<.0001
Benzodiazepine	9.4 (6.41-13.15)	1.1 (0.72-1.52)	.33 (0.14-0.72)	.0098
GI Motility	2.68 (1.19-5.09)	.3 (.1359)	0	.0246
Spread: Site 3	100	46 46 (44 04 47 40)	14 67 (40 20 42 04)	. 0004
All PIMs	100	16.16 (14.91-17.40)	11.67 (10.30-13.04)	<.0001
Skeletal Muscle Relaxant	33.3 (29.41-37.48)	5.4 (4.64-6.18)	3.2 (2.51-4.05)	.0003
Anticholinergic Antihistamine	40.4 (36.27-44.62)	6.5 (5.70- 7.39)	4.9 (4.05- 5.92)	.0183
Benzodiazepine	8.0 (5.85-10.50)	1.3 (0.94-1.72)	.33 (0.15-0.67)	.0006
GI Motility	8.0 (5.85-10.50)	1.3 (0.94-1.72)	.76 (0.46-1.21)	.0897
Non-Steroidal Anti- Inflammatory Drugs	5.6 (3.81-7.80)	0.9 (0.61-1.27)	.95 (0.60-1.45)	.9613



^{*}in preparation

Informing EQUIPPED Dissemination

- Promising early results of EQUIPPED
- Personnel effort to provide academic detailing-based audit and feedback may be challenging

 - Lack of geriatric prescribing expertise
 - **A** Challenges reaching all prescribers
- Clinical dashboards have become more available
- Study Question: Could EQUIPPED audit and feedback be delivered in a more automated way and still be effective?



VA HSR&D AWARD (FY19-22)



8VA Emergency Departments

Randomly assigned to receive EQUIPPED with Academic Detailing or Dashboard Audit and Feedback





Dashboard Feedback

Monthly provider feedback via an electronic dashboard with audit, feedback and peer benchmarking




Academic Detailing Feedback

One-to-one (I:I) in-person academic detailing from a professional colleague that includes in-person audit, feedback, and peer benchmarking and provide on-site engagement

To compare the effectiveness of active vs passive feedback EQUIPPED intervention by comparing the monthly proportion of PIM prescribing as % of individual prescriptions) in each arm.



To evaluate the effectiveness of the active vs passive feedback EQUIPPED interventions using semistructured qualitative telephone interviews and quantitative survey data.







Evaluate Provider Audit & Feedback Strategy

Differences between Aca	Differences between Academic Detailing EQUIPPED and Dashboard EQUIPPED						
Component	EQUIPPED – Academic Detailing	EQUIPPED - Dashboard					
Education	Individual 1:1 academic detailing from a local clinical EQUIPPED champion	Emailed individual prescribing reports with suggestions for PIM alternatives provided via a PIM dashboard					
Peer Benchmarking	Providers whose monthly PIM percentage is more than 1 standard deviation worse than the site mean, may receive additional 1:1 academic detailing from a local clinical EQUIPPED champion	Email notification regarding peer benchmarking data sent via PIM dashboard					
Provider Feedback	EQUIPPED clinical champion intentionally engages ED providers during 1:1 sessions to determine local site factors and processes that impact prescribing behavior	ED providers may elect to notify ED leadership or EQUIPPED site champion regarding local site factors and processes that impact prescribing behavior					
Expert Consultation	EQUIPPED clinical investigators will be provide rapid feedback on questions arising from 1:1 sessions (e.g. discussion alternative medications)	General information on the EQUIPPED intervention and Beers Criteria will be provided					

Vaughan CP et al. Acad Emerg Med 2023



VA HSRD Results






Figure 1. Simplified diagram of the Enhancing Quality of Prescribing Practices for Older Veterans Discharged From the Emergency Department (EQUIPPED) dashboard extract, load, transform process. CDW = Corporate Data Warehouse; ED = emergency department; EHR = electronic health record.



VA HSRD Dashboard Audit and Feedback

- Automated, personalized email to individual prescriber on the first Tuesday of the month
- Provided monthly PIM % relative to baseline and target of < 5%
- Provided link to the dashboard for patient-specific information









Baseline Characteristics of 8 Implementation Sites

Academic Detailing n=4



Group baseline PIM% 8.01%

	Academic Detailing					
	Site A	Site B	Site C	Site D		
Total number of Encounters FY '21	12,149	21,278	17,387	11,914		
% FY21 Encounters	7,223	10,321	10,064	6,845		
Veterans >=65 yrs old	(59%)	(48%)	(58%)	(57%)		
% of admissions FY21 Veterans >=65 yrs old	45.82%	21.55%	26.43%	41.22%		
Six-month baseline PIM prescribing %	5.50%	8.90%	9.65%	7.49%		
Site Champion Title	Associate Director for Clinical Affairs GRECC	Section Chief Emergency Medicine	ED Clinician	Director of Geriatric Emergency Medicine		

Dashboard n=4



Group baseline PIM% 8.04%

	Dashboard				
	Site E	Site F	Site G	Site H	
Total number of Encounters FY '21	39,162	25,505	20,220	18,445	
% FY21 Encounters Veterans	16,841	11,007	11,937	9,750	
>=65 yrs old	(43%)	(43%)	(59%)	(54%)	
% of admissions FY21 Veterans >=65 yrs old	34.77%	18.13%	42.95%	29.49%	
Six-month baseline PIM prescribing %	7.83%	8.42%	6.63%	10.49%	
Site Champion Title	Section Chief of Quality, Training and Education	Director of the Geriatric ED	Associate Director Clinical GRECC	Chief Emergency Medicine Service	

Prescribing Outcomes 12 months after Implementation





OVERALL RESULTS	Total Discharge Prescriptions for Veterans 65 years and older	Total PIM Prescriptions for Veterans 65 years and older	% PIMs	Within group ^α and Between group ^β p-value
ACADEMIC DETAILING				
Baseline	17,744	1,421	8.01	
Implementation	16,909	1,220	7.22	
Post-implementation	23,648	1,672	7.07	0.0006^{α}
DASHBOARD				
Baseline	26,936	2,166	8.04	
Implementation	16,503	1,280	7.76	
Post-implementation	36,795	2,979	8.10	0.81^{α}
				<0.0001 ^β

Dashboard sites had 14% higher odds of prescribing PIMs 12 months after implementation of EQUIPPED audit and feedback OR=1.14 (95% CI 1.08-1.22)



Limitations

- Only able to evaluate 12 months of prescribing data based on funding timeline
- Not feasible to continually update audit and feedback based on staffing fluctuations
 - Providers receiving audit and feedback determined by site
 Champion at baseline
- Implementation during COVID pandemic was disruptive; however, reflects real-world realities

Exploratory Analysis

- Providers to receive audit and feedback determine by site Champion at baseline
 - More likely to be staff providers than moonlighters or resident trainees
- Academic Detailing sites: 79/638 (12.4%) received audit and feedback
- <u>Dashboard sites:</u> 86/548 (15.7%) received audit and feedback

- Prescribers receiving feedback accounted for ~60% of prescriptions in both groups
- Did prescribing results differ based on receipt of audit and feedback?



Analysis Limited to Prescribers Receiving Feedback





OVERALL RESULTS	Total Discharge Prescriptions for Veterans 65 years and older	Total PIM Prescriptions for Veterans 65 years and older	% PIMs	Within group ^α and Between group ^β p-value
ACADEMIC DETAILING				
Baseline	10,280	824	8.02	
Implementation	9,991	772	7.22	
Post-implementation	14,576	981	6.73	0.0002^{α}
DASHBOARD				
Baseline	15,958	1,317	8.25	
Implementation	9,105	617	6.78	
Post-implementation	21,639	1,383	6.39	<0.0001α
				0.22^{β}





Additional Implementation Considerations (preliminary findings)

Factors Facilitating Implementation

- All sites have large populations of geriatric patients in the ED
- Initial leadership engagement/endorsement
- All sites reported training providers before EQUIPPED started
- EQUIPPED supported ACEP Geriatric ED accreditation(6 of 8 sites)
- 4 of 8 sites received VA Office of Geriatrics and Extended Care supplemental funding
- Centralized facilitation team and tools that were reviewed by national and local experts
- Order sets could be adapted based on local needs and provider preferences

Bottom Line

- Generally high degree of reported organizational readiness for change (change viewed as important and feasible)
- Generally reported that EQUIPPED is in line with organizational goals
- Facilitation and tools are available



Additional Implementation Considerations (preliminary findings)

Barriers to Implementation and Impact of COVID-19 Pandemic

- All sites implemented EQUIPPED during the COVID-19 pandemic
- Sites were identified and planning started at most prior to the pandemic
- 1 initially identified site dropped out of the project Experienced change in leadership
- Lower patient volumes during the early part of COVID allowed more time to start new projects
- Patients in the ED were higher acuity and fewer were discharged
- Individuals pulled to different duties (e.g., informatics team need to make changes to the electronic health record)
- Engaging frontline staff during COVID was challenging (e.g. low response rates for surveys of providers)
 - Learning new ways of caring for patients across the board
 - Life challenges faced as a result of COVID
 - Important both in relation to delivery of feedback and discussions related to the balance between guideline concordant care and clinical judgement



Conclusions

Academic detailing approach more effective at group level

- Dashboard approach may be reasonable w/limited resources
 - Consider automatic prescriber enrollment during onboarding

- Results suggest EQUIPPED well-suited for ED setting of care
 - Implementation evaluation of facilitators and barriers pending



TEAM MEMBERS – THANK YOU!!

Atlanta/Grady/Emory

Melissa Stevens*
Camille Vaughan*
Edidiong Ikpe-Ekpo
Anna Vandenberg*
Katherina Echt
Carolyn Clevenger
Dan Wu

Debbie Vigliotti Nick Stanley Shami Das*

Anita Schmidt

DeWayne Cross

Christine Jasien
Purvi Patel

Lawanda Kemp

Michelle Kegler

Traci Leong

Jessica Kelleher

Andre Bosman

Kayla Burrell

Roslyn Seitz

Christele Francois

Jennie Mather

Bronx/Mt. Sinai

William Hung*

Ula Hwang*

Kenneth Boockvar

Noor Fattouh

Eve Gottesman

William Ho

Shujun Xia

Denise Nassisi

Nick Genes

Martine Sanon

Central Alabama/Birmingham

Gerald Thomas
Garrett Aikens
Felecia Ivory
Alayne Markland*
Gerald McGwin
Casey Waite
Alex Lo
Kathy Burgio
Rachel Skains

Durham/Asheville/Duke

Nicole Hastings*
Molly McGaughey*
William Bryan
Stephanie Eucker
Janet Wooten
Kelly Knapp
Jason Moss
Ryan Owenby
Heather King
William Knaack
Sherman Lee
George Jackson
Isis Morris
Jennifer Chapman

Salt Lake City

Zach Burningham

> Lexington/Louisville

Jeff Violette*
Patrick Cellarosi-Yorba
Amy Minix*
Tracy Putman

Nashville/ Murfreesboro

James Powers*
Vincent Messina
Jason Denton
Kiffany Peggs
Joyline James

Orlando/Gainesville

Veronica Sikka*
Adam Golden*
Karen Sotace
Jacquelyn Brenner
Rebecca Beyth*

New Orleans/Shreveport

Joy Cohen* Alan Sorkey*

Denver

Lauren Abbate*
Andrea Daddato

Boston

Jane Driver*
Chi Mac

Charleston

Lancer Scott*
Robert Lake
Ellika Bengtson
Cailin Lutz
Sharon Castle

San Antonio/Dallas

Sara Espinoza*
Daniel MacCarthy
Heather Blacksmith
Rohit Manaktala*
Stephen Burgher
Jaimie Ostrom

Cleveland

Gerald Maloney*

* Site Coordinator or EQUIPPED Mentor

